A new analysis presented at a major endocrinology conference suggests that popular GLP-1 weight-loss medications could carry an unexpected benefit for men struggling with fertility issues related to obesity.

Researchers at the Endocrine Society’s ENDO 2026 meeting in Chicago examined data connecting GLP-1 treatments with male reproductive health.

The findings indicate that men taking these drugs may see improvements in testosterone levels, sperm quality, and overall metabolic health.

Obesity has long been tied to reduced fertility in men because it can disrupt the hormone system that controls testosterone production.

Here's What They're Not Telling You About Your Retirement

This hormonal dysregulation, known as functional hypogonadism, can lower testosterone and diminish semen quality.

To explore whether GLP-1 drugs could alter reproductive outcomes, scientists conducted a systematic review of five randomized controlled trials involving men between 18 and 65 who were prescribed one of the medications. The studies evaluated hormone levels, metabolic factors, and semen parameters.

Measurements included testosterone, brain hormones involved in sperm production, proteins that transport sex hormones, and overall indicators like weight, BMI, cholesterol, and blood sugar.

Findings from these trials offered a consistent pattern of potential reproductive benefit tied to weight loss.

This Could Be the Most Important Video Gun Owners Watch All Year

In one four-week trial using dulaglutide, researchers found no significant differences in reproductive hormones or sexual function, suggesting that the drug did not disturb male hormonal balance.

A separate 16-week study of liraglutide reported hormone improvements among obese men with functional hypogonadism, with the drug showing greater health gains than standard hormone replacement therapy. Another investigation into liraglutide found increases in sperm concentration and count.

The review further noted that a 24-week semaglutide trial, involving drugs such as Ozempic and Wegovy, led to improvements in sperm shape and reductions in harmful cholesterol while maintaining testosterone levels. Semaglutide’s outcomes suggested a concurrent enhancement of reproductive and metabolic health factors.

Overall, the study authors concluded that GLP-1 drugs “do not appear to acutely suppress the male HPG axis and may improve reproductive hormones and semen parameters in obese hypogonadal men, largely within the context of weight loss.”

However, they cautioned that the dataset remains small, emphasizing the need for more comprehensive research.

“Evidence remains limited and heterogeneous, underscoring the need for larger RCTs explicitly powered to assess male reproductive outcomes,” the authors wrote in their abstract.

Despite these early limitations, the trend points toward a possible new pathway linking weight management drugs with male fertility.

Dr. Anthony Puopolo, a men’s health expert and lead medical provider for RexMD, reflected on the results, noting, “This provides early evidence that GLP-1 medications taken by obese men with hypogonadism/low testosterone (low T) improves testosterone levels.”

He added that if additional studies confirm the finding, GLP-1 medications could represent a valuable alternative for obese men seeking fertility-friendly treatments.

“If this finding continues to gain evidence, GLP-1s might be a better option for low T than testosterone replacement therapy (TRT) in obese men – as GLP-1 medications preserve fertility, whereas TRT tends to be harmful to male reproductive/sperm function,” he said.

Dr. Brian Slomovitz of Mount Sinai Medical Center also weighed in more broadly on the potential of GLP-1 drugs, saying the emerging data on these medications and reduced disease risk is “not surprising.”

His comment underscored growing clinical interest in this class of drugs well beyond weight control.

While further studies are needed, the early evidence presented at ENDO 2026 points to a potentially promising, if still developing, connection between metabolic treatments and reproductive health in men.

For now, the research suggests that maintaining hormonal balance while losing weight might have benefits that extend unexpectedly into male fertility.